drugset / Trial / NCT05063318
Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors
RandomizedCrossoverOpen-labelTreatment
Summary
Prospective, open-label, two-way crossover, phase Ib drug-drug interaction study in patients with advanced solid tumors
Timeline
- Start
- 2020-10-07
- Primary completion
- 2022-04-21
- Completion
- 2022-04-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Itraconazole | Small molecule | — | — |
| Comparator | Lurbinectedin | Other / unclassified | 0.8 mg/m2 | — |
| Comparator | Lurbinectedin | Other / unclassified | 3.2 mg/m2 | — |